Moderna, Bird Flu

Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.
Moderna Receives $590M From HHS To Develop Bird Flu Vaccine
TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
U.S. pays $590 million to Moderna to speed up development of bird flu vaccine
The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top priority for the federal government.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.
Moderna secures $590M in government funding to develop bird flu vaccine
The U.S. government has awarded Moderna $590 million to help speed up the development of a bird flu vaccine. President Trump ends marathon inauguration day at three inaugural balls José Andrés Says This Is the Best Substitute for Salt Macron announces plan for mobilization of volunteers Real-life “Yellowstone” cowboy went from sleeping in a tent to a building a TV empire New Bears coach Ben Johnson eyeing two former NFL head coaches for his staff in Chicago,
US provides $72M to vaccine manufacturers to advance bird flu shot preparedness
Federal health officials announced Friday they are providing $72 million to vaccine manufacturers to help ... the country ...
CNN4d
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In July, the company received $176 million from HHS toward its ...
Medscape5d
The Evolving History of Influenza Viruses and Influenza Vaccines
This virus was named Influenza B and the inactivated influenza ... became the technique that was used by commercial manufacturers. A vaccine was manufactured according to this procedure ...
Nature1mon
Influenza vaccine market dynamics
However, as the demand for seasonal influenza vaccination in the general population has failed to meet the expectations of suppliers, oversupply of these vaccines in the United States has become ...
Forbes27d
Influenza Viruses: What’s In A Name?
Why You Need A Flu Vaccine Every Year The phenomena of antigenic drift and antigenic shift are why public health authorities recommend getting an influenza vaccine each year. Every year ...
GEN6d
Maritime History Holds the Key to a Vaccine Manufacturing Powerhouse
The historical role of the British city of Liverpool as a trading port has helped it to become a center of excellence for vaccine manufacturing.